NASDAQ:CBIO
Delisted
Catalyst Biosciences Stock News
$0.511
+0 (+0%)
At Close: Dec 14, 2023
Chardan Capital Sticks to Their Buy Rating for uniQure (QURE)
06:50am, Wednesday, 29'th Jan 2020
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QURE – Research Report) today and set a price
Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress
01:00pm, Monday, 27'th Jan 2020
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of.
Audentes Therapeutics (BOLD) Gets a Hold Rating from Chardan Capital
12:13pm, Monday, 20'th Jan 2020
Chardan Capital analyst
Gbola Amusa
maintained a
Hold
rating on Audentes Therapeutics (
BOLD
–
Research Report
) on January 18. The company’s shares closed last Monday at $59.97, close to its 52-w
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors
01:00pm, Friday, 17'th Jan 2020
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey
20 Biopharma Stocks for Huge Upside Potential in 2020
12:05pm, Saturday, 11'th Jan 2020
Here are 20 biotechnology and pharmaceutical stocks that have been given big analyst upside targets for 2020.
Imagine Owning Catalyst Biosciences (NASDAQ:CBIO) And Wondering If The 31% Share Price Slide Is Justified
06:12pm, Monday, 30'th Dec 2019
It is a pleasure to report that the Catalyst Biosciences, Inc. (NASDAQ:CBIO) is up 38% in the last quarter. But that...
Company News For Dec 20, 2019
04:10pm, Friday, 20'th Dec 2019
Companies In The News Are: CAG, CBIO, MLHR, DRI
Catalyst Biosciences Inc (CBIO): Hedge Fund Sentiment Unchanged But Bullish
02:34am, Friday, 20'th Dec 2019
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and
